Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2013 2
2014 2
2017 1
2022 2
2023 2
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Epidemiology, Clinical Features, and Antimicrobial Resistance of Invasive Escherichia Coli Disease in Patients Admitted in Tertiary Care Hospitals.
Doua J, Geurtsen J, Rodriguez-Baño J, Cornely OA, Go O, Gomila-Grange A, Kirby A, Hermans P, Gori A, Zuccaro V, Gravenstein S, Bonten M, Poolman J, Sarnecki M. Doua J, et al. Open Forum Infect Dis. 2023 Jan 27;10(2):ofad026. doi: 10.1093/ofid/ofad026. eCollection 2023 Feb. Open Forum Infect Dis. 2023. PMID: 36817744 Free PMC article.
Safety, Reactogenicity, Immunogenicity, and Dose Selection of 10-Valent Extraintestinal Pathogenic Escherichia coli Bioconjugate Vaccine (VAC52416) in Adults Aged 60-85 Years in a Randomized, Multicenter, Interventional, First-in-Human, Phase 1/2a Study.
Fierro CA, Sarnecki M, Doua J, Spiessens B, Go O, Davies TA, van den Dobbelsteen G, Poolman J, Abbanat D, Haazen W. Fierro CA, et al. Among authors: doua j. Open Forum Infect Dis. 2023 Aug 11;10(8):ofad417. doi: 10.1093/ofid/ofad417. eCollection 2023 Aug. Open Forum Infect Dis. 2023. PMID: 37608916 Free PMC article.
Feasibility of tracking invasive Escherichia coli disease among older adults in a community setting: A prospective observational study.
Doua J, Ekkelenkamp M, Verheij T, Go O, Ruhmel S, Leathers K, Spiessens B, van Rooij S, Fowler VG Jr, Geurtsen J, Dolor R, Sarnecki M, Chatterjee R, Poolman J, Bonten M; on behalf COMBACTE-NET consortium/EXPECT study group. Doua J, et al. Eur J Clin Microbiol Infect Dis. 2024 Mar;43(3):541-550. doi: 10.1007/s10096-023-04738-y. Epub 2024 Jan 18. Eur J Clin Microbiol Infect Dis. 2024. PMID: 38236365 Free PMC article.
Clinical presentation and antimicrobial resistance of invasive Escherichia coli disease in hospitalized older adults: a prospective multinational observational study.
Doua J, Rodríguez-Baño J, Froget R, Puranam P, Go O, Geurtsen J, van Rooij S, Vilken T, Minoru I, Yasumori I, Spiessens B, Tacconelli E, Biehl LM, Thaden JT, Sarnecki M, Goossens H, Poolman J, Bonten M, Ekkelenkamp M; COMBACTE-NET Consortium/EXPECT Study Group. Doua J, et al. Infection. 2024 Jan 25. doi: 10.1007/s15010-023-02163-z. Online ahead of print. Infection. 2024. PMID: 38267801
Lot-to-lot consistency, immunogenicity, and safety of the Ad26.ZEBOV, MVA-BN-Filo Ebola virus vaccine regimen: A phase 3, randomized, double-blind, placebo-controlled trial.
Goldstein N, McLean C, Gaddah A, Doua J, Keshinro B, Bus-Jacobs L, Hendriks J, Luhn K, Robinson C, Douoguih M. Goldstein N, et al. Among authors: doua j. Hum Vaccin Immunother. 2024 Dec 31;20(1):2327747. doi: 10.1080/21645515.2024.2327747. Epub 2024 Mar 24. Hum Vaccin Immunother. 2024. PMID: 38523332 Free PMC article. Clinical Trial.
Efficacy and safety of intermittent preventive treatment in schoolchildren with sulfadoxine/pyrimethamine (SP) and SP plus piperaquine in Democratic Republic of the Congo: a randomised controlled trial.
Matangila JR, Doua JY, Mitashi P, da Luz RI, Lutumba P, Van Geertruyden JP. Matangila JR, et al. Among authors: doua jy. Int J Antimicrob Agents. 2017 Mar;49(3):339-347. doi: 10.1016/j.ijantimicag.2016.11.017. Epub 2017 Jan 17. Int J Antimicrob Agents. 2017. PMID: 28108368 Clinical Trial.
11 results